

Insulin resistance drives hepatic de novo lipogenesis in

Journal of Clinical Investigation

130, 1453-1460

DOI: [10.1172/jci134165](https://doi.org/10.1172/jci134165)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Playing Jekyll and Hyde—The Dual Role of Lipids in Fatty Liver Disease. <i>Cells</i> , 2020, 9, 2244.	4.1	4
2	Dietary protein intake and obesity-associated cardiometabolic function. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2020, 23, 380-386.	2.5	10
3	Lifestyle interventions affecting hepatic fatty acid metabolism. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2020, 23, 373-379.	2.5	6
4	Dysregulated lipid metabolism links NAFLD to cardiovascular disease. <i>Molecular Metabolism</i> , 2020, 42, 101092.	6.5	197
5	(âˆ™)-Epicatechin and the comorbidities of obesity. <i>Archives of Biochemistry and Biophysics</i> , 2020, 690, 108505.	3.0	24
6	Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. <i>Molecular Metabolism</i> , 2021, 50, 101122.	6.5	135
7	Organismal Fructose Metabolism in Health and Non-Alcoholic Fatty Liver Disease. <i>Biology</i> , 2020, 9, 405.	2.8	11
8	Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD. <i>Molecular Metabolism</i> , 2021, 50, 101115.	6.5	106
9	The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). <i>Journal of Diabetes Research</i> , 2020, 2020, 1-16.	2.3	196
10	Effects of Diet versus Gastric Bypass on Metabolic Function in Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 721-732.	27.0	164
11	Metabolic drivers of non-alcoholic fatty liver disease. <i>Molecular Metabolism</i> , 2021, 50, 101143.	6.5	99
12	Mitochondrial oxidative function in NAFLD: Friend or foe?. <i>Molecular Metabolism</i> , 2021, 50, 101134.	6.5	53
13	Perspectives on youth-onset nonalcoholic fatty liver disease. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00184.	2.4	26
14	The small intestine shields the liver from fructose-induced steatosis. <i>Nature Metabolism</i> , 2020, 2, 586-593.	11.9	81
15	Rapamycin-Loaded mPEG-PLGA Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-alcoholic Fatty Liver Disease. <i>Frontiers in Chemistry</i> , 2020, 8, 407.	3.6	31
16	Exercise and metabolic health: beyond skeletal muscle. <i>Diabetologia</i> , 2020, 63, 1464-1474.	6.3	134
17	Tracing insights into de novo lipogenesis in liver and adipose tissues. <i>Seminars in Cell and Developmental Biology</i> , 2020, 108, 65-71.	5.0	53
18	Using total plasma triacylglycerol to assess hepatic <i>de novo</i> lipogenesis as an alternative to VLDL triacylglycerol. <i>Upsala Journal of Medical Sciences</i> , 2020, 125, 211-216.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Surprising findings in a "well-understood"™ nutrient-assimilation pathway. <i>Nature Metabolism</i> , 2020, 2, 561-563.	11.9	1
20	&lt;p&gt;Glucocorticoid-Induced Fatty Liver Disease&lt;/p&gt;; Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 1133-1145.	2.4	70
21	Evolving Role for Pharmacotherapy in NAFLD/NASH. <i>Clinical and Translational Science</i> , 2021, 14, 11-19.	3.1	86
22	A review of non-alcoholic fatty liver disease in non-obese and lean individuals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1497-1507.	2.8	43
23	Total-body PET Imaging. <i>PET Clinics</i> , 2021, 16, 75-87.	3.0	7
24	Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease. <i>Diabetes Care</i> , 2021, 44, 489-498.	8.6	42
25	Inhibition of fatty acid synthase with <scp>FT&€101</scp> safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 700-710.	4.4	35
26	Fish oil suppresses obesity more potently in lean mice than in diet-induced obese mice but ameliorates steatosis in such obese mice. <i>Bioscience, Biotechnology and Biochemistry</i> , 2021, 85, 421-429.	1.3	2
27	Understanding the Alterations in Lipid Metabolism in NAFLD Progression: Current Trends and Future Directions. <i>Critical Reviews in Oncogenesis</i> , 2021, 26, 35-49.	0.4	8
28	GH directly inhibits steatosis and liver injury in a sex-dependent and IGF1-independent manner. <i>Journal of Endocrinology</i> , 2021, 248, 31-44.	2.6	19
29	Adaptive and maladaptive roles for ChREBP in the liver and pancreatic islets. <i>Journal of Biological Chemistry</i> , 2021, 296, 100623.	3.4	22
30	Adipose Insulin Resistance and Decreased Adiponectin Are Correlated With Metabolic Abnormalities in Nonobese Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2228-e2238.	3.6	5
31	Sodium Butyrate Supplementation Inhibits Hepatic Steatosis by Stimulating Liver Kinase B1 and Insulin-Induced Gene. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 857-871.	4.5	36
32	The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories?. <i>Frontiers in Nutrition</i> , 2021, 8, 640557.	3.7	44
33	Roles of Ceramides in Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 792.	2.4	44
34	Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics. <i>Nature Reviews Endocrinology</i> , 2021, 17, 276-295.	9.6	198
35	The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2020, 11, 601627.	3.5	50
36	Resveratrol Improves Liver Steatosis and Insulin Resistance in Non-alcoholic Fatty Liver Disease in Association With the Gut Microbiota. <i>Frontiers in Microbiology</i> , 2021, 12, 611323.	3.5	25

#	ARTICLE	IF	CITATIONS
37	Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent. Trends in Pharmacological Sciences, 2021, 42, 183-190.	8.7	22
38	Relationship between de novo lipogenesis and serum sex hormone binding globulin in humans. Clinical Endocrinology, 2021, 95, 101-106.	2.4	11
39	Dietary Macronutrient Composition Differentially Modulates the Remodeling of Mitochondrial Oxidative Metabolism during NAFLD. Metabolites, 2021, 11, 272.	2.9	6
40	Role of 2â€series prostaglandins in the pathogenesis of type 2 diabetes mellitus and nonâ€alcoholic fatty liver disease (Review). International Journal of Molecular Medicine, 2021, 47, .	4.0	22
41	Advances in Understanding of the Role of Lipid Metabolism in Aging. Cells, 2021, 10, 880.	4.1	60
42	Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. Current Opinion in Lipidology, 2021, 32, 200-206.	2.7	10
43	Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 2021, 372, 1224-1229.	12.6	192
44	The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. Nutrients, 2021, 13, 1314.	4.1	34
45	Role of Insulin Resistance in MAFLD. International Journal of Molecular Sciences, 2021, 22, 4156.	4.1	131
46	Lingonberry Improves Non-Alcoholic Fatty Liver Disease by Reducing Hepatic Lipid Accumulation, Oxidative Stress and Inflammatory Response. Antioxidants, 2021, 10, 565.	5.1	15
47	Acetyl-CoA and Metabolite Fluxes Regulate White Adipose Tissue Expansion. Trends in Endocrinology and Metabolism, 2021, 32, 320-332.	7.1	16
48	A guide to understanding endoplasmic reticulum stress in metabolic disorders. Molecular Metabolism, 2021, 47, 101169.	6.5	134
49	Liver macrophages and inflammation in physiology and physiopathology of nonâ€alcoholic fatty liver disease. FEBS Journal, 2022, 289, 3024-3057.	4.7	37
50	The relationships of sex hormoneâ€binding globulin, total testosterone, androstenedione and free testosterone with metabolic and reproductive features of polycystic ovary syndrome. Endocrinology, Diabetes and Metabolism, 2021, 4, e00267.	2.4	9
51	Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review. Metabolites, 2021, 11, 353.	2.9	19
52	The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease. Experimental and Molecular Medicine, 2021, 53, 809-822.	7.7	12
53	Adipose tissue and insulin resistance in obese. Biomedicine and Pharmacotherapy, 2021, 137, 111315.	5.6	240
54	Association Between the Triglycerideâ€Glucose Index and Outcomes of Nonalcoholic Fatty Liver Disease: A Large-Scale Health Management Cohort Study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 2829-2839.	2.4	10

#	ARTICLE	IF	CITATIONS
55	Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2021, 17, 484-495.	9.6	224
56	Therapeutic opportunities for pancreatic $\beta$ -cell ER stress in diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2021, 17, 455-467.	9.6	106
57	Measurement of lipogenic flux by deuterium resolved mass spectrometry. <i>Nature Communications</i> , 2021, 12, 3756.	12.8	18
58	Increased Adipose Tissue Fibrogenesis, Not Impaired Expandability, Is Associated With Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2021, 74, 1287-1299.	7.3	25
59	Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6949.	4.1	10
60	Brain insulin signalling in metabolic homeostasis and disease. <i>Nature Reviews Endocrinology</i> , 2021, 17, 468-483.	9.6	70
61	The influence of nutritional state on the fatty acid composition of circulating lipid fractions: implications for their use as biomarkers of dietary fat intake. <i>Upsala Journal of Medical Sciences</i> , 2021, 126, .	0.9	1
62	Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis. <i>Advanced Drug Delivery Reviews</i> , 2021, 174, 127-139.	13.7	16
63	The solution to obesity and type 2 diabetes: reversing insulin resistance. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2021, .	0.7	0
64	Dietary carbohydrates and fats in nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 770-786.	17.8	108
65	Subcutaneous Adipose Tissue Metabolic Function and Insulin Sensitivity in People With Obesity. <i>Diabetes</i> , 2021, 70, 2225-2236.	0.6	13
66	Response to Comment on "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women". <i>Science</i> , 2021, 373, .	12.6	0
67	Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes. <i>Hepatology</i> , 2021, 74, 1845-1863.	7.3	16
68	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021, 161, 1475-1486.	1.3	101
69	Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. <i>Seminars in Liver Disease</i> , 2021, 41, 421-434.	3.6	55
70	<i>Chop</i> / <i>Ddit3</i> depletion in $\beta$ cells alleviates ER stress and corrects hepatic steatosis in mice. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	38
71	Multiple antisense oligonucleotides targeted against monoacylglycerol acyltransferase 1 (Mogat1) improve glucose metabolism independently of Mogat1. <i>Molecular Metabolism</i> , 2021, 49, 101204.	6.5	8
72	Aquaporins in insulin resistance and diabetes: More than channels!. <i>Redox Biology</i> , 2021, 44, 102027.	9.0	21

#	ARTICLE	IF	CITATIONS
73	A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3676-3688.	2.3	11
74	NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. <i>Cells</i> , 2021, 10, 2034.	4.1	20
75	Bi-directional and temporal relationship between elevated alanine aminotransferase and hypertension in a longitudinal study of Chinese adults. <i>Clinical and Experimental Hypertension</i> , 2021, 43, 750-757.	1.3	3
76	Fatty liver index as a predictor for type 2 diabetes in subjects with normoglycemia in a nationwide cohort study. <i>Scientific Reports</i> , 2021, 11, 16453.	3.3	5
77	Amelioration of Hepatic Steatosis in Mice through <i>Bacteroides uniformis</i> CBA7346-Mediated Regulation of High-Fat Diet-Induced Insulin Resistance and Lipogenesis. <i>Nutrients</i> , 2021, 13, 2989.	4.1	15
78	Hepatic sexual dimorphism "implications for non-alcoholic fatty liver disease. <i>Nature Reviews Endocrinology</i> , 2021, 17, 662-670.	9.6	41
79	The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC). <i>Cureus</i> , 2021, 13, e17320.	0.5	3
80	Metabolic-associated fatty liver disease and lipoprotein metabolism. <i>Molecular Metabolism</i> , 2021, 50, 101238.	6.5	195
81	Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes. <i>Current Diabetes Reviews</i> , 2021, 17, e110320187539.	1.3	11
82	Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis. <i>Current Atherosclerosis Reports</i> , 2021, 23, 72.	4.8	19
83	Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD. <i>Hepatology</i> , 2021, 74, 3472-3478.	7.3	21
84	Acute carbohydrate overfeeding: a redox model of insulin action and its impact on metabolic dysfunction in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E636-E651.	3.5	7
85	Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 889-902.	8.1	26
86	The role of hepatic lipid composition in obesity-related metabolic disease. <i>Liver International</i> , 2021, 41, 2819-2835.	3.9	23
87	Cannabinoid receptor 1 signaling in hepatocytes and stellate cells does not contribute to NAFLD. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	23
88	Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 721-730.	7.1	27
89	Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 835-856.	17.8	183
90	Effects of Oral Vitamin C Supplementation on Liver Health and Associated Parameters in Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. <i>Frontiers in Nutrition</i> , 2021, 8, 745609.	3.7	22

#	ARTICLE	IF	CITATIONS
91	Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 655-674.	4.7	8
92	Protective effects of p-coumaric acid against high-fat diet-induced metabolic dysregulation in mice. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 111969.	5.6	18
93	Anti-Diabetic Medications: A promising therapeutic approaches for the Management of NAFLD. <i>Records of Pharmaceutical and Biomedical Sciences</i> , 2021, 5, 65-70.	0.1	0
96	Lipodystrophy: A paradigm for understanding the consequences of "overloading" adipose tissue. <i>Physiological Reviews</i> , 2021, 101, 907-993.	28.8	35
97	Leptin decreases de novo lipogenesis in patients with lipodystrophy. <i>JCI Insight</i> , 2020, 5, .	5.0	35
98	Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics. <i>Journal of Clinical Investigation</i> , 2020, 130, 3305-3314.	8.2	45
99	Decreased adipose tissue oxygenation associates with insulin resistance in individuals with obesity. <i>Journal of Clinical Investigation</i> , 2020, 130, 6688-6699.	8.2	64
100	Atorvastatin promotes AMPK signaling to protect against high fat diet-induced non-alcoholic fatty liver in golden hamsters. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 2133-2142.	1.8	7
101	Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13695.	3.4	24
102	Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 526-535.	3.7	80
103	SREBP-1c and lipogenesis in the liver: an update. <i>Biochemical Journal</i> , 2021, 478, 3723-3739.	3.7	51
104	Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?. <i>World Journal of Gastroenterology</i> , 2021, 27, 6522-6526.	3.3	4
105	Molecular aspects of fructose metabolism and metabolic disease. <i>Cell Metabolism</i> , 2021, 33, 2329-2354.	16.2	100
106	A Systems Approach Dissociates Fructose-Induced Liver Triglyceride from Hypertriglyceridemia and Hyperinsulinemia in Male Mice. <i>Nutrients</i> , 2021, 13, 3642.	4.1	3
107	Role of acetylation in nonalcoholic fatty liver disease: a focus on SIRT1 and SIRT3. <i>Exploration of Medicine</i> , 2020, 1, 248-258.	1.5	4
109	The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-25.	4.0	39
110	Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets. <i>Diagnostics</i> , 2021, 11, 2053.	2.6	10
111	A short report on NCM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 889-895.	3.4	6

#	ARTICLE	IF	CITATIONS
112	Dysregulation of hepatic metabolism with obesity: factors influencing glucose and lipid metabolism. <i>Proceedings of the Nutrition Society</i> , 2022, 81, 1-11.	1.0	15
113	The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 792667.	3.5	11
114	Independent associations of thyroid-related hormones with hepatic steatosis and insulin resistance in euthyroid overweight/obese Chinese adults. <i>BMC Gastroenterology</i> , 2021, 21, 431.	2.0	7
115	Controversies surrounding peripheral cannabinoid receptor 1 in fatty liver disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	1
116	Linking liver metabolic and vascular disease via bile acid signaling. <i>Trends in Molecular Medicine</i> , 2022, 28, 51-66.	6.7	16
117	Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatography-Mass Spectrometry. <i>Laboratory Medicine</i> , 2022, 53, 360-368.	1.2	0
118	De novo lipogenesis in non-alcoholic fatty liver disease: Quantification with stable isotope tracers. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13733.	3.4	8
119	Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care. <i>Journal of Clinical Medicine</i> , 2021, 10, 5755.	2.4	9
120	Histone acetyltransferase NAA40 modulates acetyl-CoA levels and lipid synthesis. <i>BMC Biology</i> , 2022, 20, 22.	3.8	10
121	Lipogenesis inhibitors: therapeutic opportunities and challenges. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 283-305.	46.4	124
122	Insulin Clearance in Obesity and Type 2 Diabetes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 596.	4.1	17
123	Why does obesity cause diabetes?. <i>Cell Metabolism</i> , 2022, 34, 11-20.	16.2	183
124	Non-alcoholic fatty liver disease and type-2 diabetes: An update. <i>Journal of Diabetes Investigation</i> , 2022, 13, 930-940.	2.4	25
125	ER Unfolded Protein Response in Liver In Vivo Is Characterized by Reduced, Not Increased, De Novo Lipogenesis and Cholesterol Synthesis Rates with Uptake of Fatty Acids from Adipose Tissue: Integrated Gene Expression, Translation Rates and Metabolic Fluxes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1073.	4.1	3
126	Quercetin Reduces Lipid Accumulation in a Cell Model of NAFLD by Inhibiting De Novo Fatty Acid Synthesis through the Acetyl-CoA Carboxylase 1/AMPK/PP2A Axis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1044.	4.1	23
127	Menopause modulates the circulating metabolome: evidence from a prospective cohort study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1448-1459.	1.8	17
128	Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1812-1824.	3.6	32
129	Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-19.	4.0	4



#	ARTICLE	IF	CITATIONS
130	Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1625-1647.	4.5	15
131	Abelmoschus esculentus subfractions ameliorate hepatic lipogenesis and lipid uptake via regulating dipeptidyl peptidase-4 With improving insulin resistance. <i>PLoS ONE</i> , 2022, 17, e0265444.	2.5	3
132	Burmese pythons exhibit a transient adaptation to nutrient overload that prevents liver damage. <i>Journal of General Physiology</i> , 2022, 154, .	1.9	4
133	Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. <i>Nature Reviews Cardiology</i> , 2022, 19, 577-592.	13.7	59
134	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. <i>Hepatology</i> , 2022, 76, 1121-1134.	7.3	31
135	Retinoids in the Pathogenesis and Treatment of Liver Diseases. <i>Nutrients</i> , 2022, 14, 1456.	4.1	7
136	Added Fructose in Non-Alcoholic Fatty Liver Disease and in Metabolic Syndrome: A Narrative Review. <i>Nutrients</i> , 2022, 14, 1127.	4.1	22
137	Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112697.	5.6	6
138	Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis. <i>Archives of Pharmacal Research</i> , 2022, , 1.	6.3	2
139	Meta-Inflammation and De Novo Lipogenesis Markers Are Involved in Metabolic Associated Fatty Liver Disease Progression in BTBR ob/ob Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3965.	4.1	8
140	Nudix hydrolase NUDT19 regulates mitochondrial function and ATP production in murine hepatocytes. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159153.	2.4	4
141	Fatty Acid Synthase Inhibitor Platensimycin Intervenes the Development of Nonalcoholic Fatty Liver Disease in a Mouse Model. <i>Biomedicines</i> , 2022, 10, 5.	3.2	7
143	Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. <i>Nature Metabolism</i> , 2021, 3, 1596-1607.	11.9	147
144	Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. <i>FASEB Journal</i> , 2022, 36, e22060.	0.5	9
145	Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study. <i>Cell Reports Medicine</i> , 2021, 2, 100474.	6.5	12
146	Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	33
147	Omega-3 mechanism of action in inflammation and endoplasmic reticulum stress in mononuclear cells from overweight non-alcoholic fatty liver disease participants: study protocol for the "Brazilian Omega Study (BROS)" a randomized controlled trial. <i>Trials</i> , 2021, 22, 927.	1.6	4
148	It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13424.	4.1	61

#	ARTICLE	IF	CITATIONS
149	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 101161ATV0000000000000153.	2.4	167
150	Complex regulation of fatty liver disease. <i>Science</i> , 2022, 376, 247-248.	12.6	4
151	Caffeine Ameliorates AKT-Driven Nonalcoholic Steatohepatitis by Suppressing <i>De Novo</i> Lipogenesis and MyD88 Palmitoylation. <i>Journal of Agricultural and Food Chemistry</i> , 2022, 70, 6108-6122.	5.2	4
152	Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis. <i>Annual Review of Nutrition</i> , 2022, 42, 91-113.	10.1	20
153	Interaction effect between NAFLD severity and high carbohydrate diet on gut microbiome alteration and hepatic <i>de novo</i> lipogenesis. <i>Gut Microbes</i> , 2022, 14, .	9.8	18
154	Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application. <i>Pharmaceutical Research</i> , 2022, 39, 1789-1802.	3.5	4
155	Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 391-401.	4.7	9
156	Extracellular Vesicles in Pathogenesis and Treatment of Metabolic Associated Fatty Liver Disease. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	1
157	Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. <i>Nature Medicine</i> , 2022, 28, 1432-1438.	30.7	23
158	Apolipoprotein F is reduced in humans with steatosis and controls plasma triglyceride-rich lipoprotein metabolism. <i>Hepatology</i> , 2023, 77, 1287-1302.	7.3	3
159	The Human Milk Oligosaccharide 2- $\alpha$ -Fucosyllactose Alleviates Liver Steatosis, ER Stress and Insulin Resistance by Reducing Hepatic Diacylglycerols and Improved Gut Permeability in Obese Ldlr <sup>-/-</sup> Leiden Mice. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	10
160	Adaptation of Oxidative Phosphorylation Machinery Compensates for Hepatic Lipotoxicity in Early Stages of MAFLD. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6873.	4.1	4
161	NAFLD: Mechanisms, Treatments, and Biomarkers. <i>Biomolecules</i> , 2022, 12, 824.	4.0	86
162	Isoschaftoside Reverses Nonalcoholic Fatty Liver Disease via Activating Autophagy In Vivo and In Vitro. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-12.	1.2	2
163	KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid. <i>Biomedicines</i> , 2022, 10, 1517.	3.2	6
164	Noninvasive NMR/MRS Metabolic Parameters to Evaluate Metabolic Syndrome in Rats. <i>Diagnostics</i> , 2022, 12, 1621.	2.6	0
165	Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients. <i>Journal of Lipid Research</i> , 2022, 63, 100250.	4.2	7
166	Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2022, 28, 3243-3257.	3.3	16

#	ARTICLE	IF	CITATIONS
167	Berberrubine, a Main Metabolite of Berberine, Alleviates Non-Alcoholic Fatty Liver Disease via Modulating Glucose and Lipid Metabolism and Restoring Gut Microbiota. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	15
168	Intervention with isoleucine or valine corrects hyperinsulinemia and reduces intrahepatic diacylglycerols, liver steatosis, and inflammation in Ldlr <sup>-/-</sup> .Leiden mice with manifest obesity-associated NASH. <i>FASEB Journal</i> , 2022, 36, .	0.5	16
169	Intrahepatic triglyceride content: influence of metabolic and genetics drivers. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2022, 25, 241-247.	2.5	6
170	Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives. <i>Biochemical Pharmacology</i> , 2022, 202, 115157.	4.4	19
171	The aqueous extract of Phragmites rhizome improves hepatic steatosis in obese mice via the AMPK-mediated inhibition of ER stress. <i>Journal of Functional Foods</i> , 2022, 95, 105164.	3.4	1
172	Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD). <i>Metabolism: Clinical and Experimental</i> , 2022, 134, 155246.	3.4	12
173	Redox-Unlockable Nanoparticle-Based MST1 Delivery System to Attenuate Hepatic Steatosis via the AMPK/SREBP-1c Signaling Axis. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 34328-34341.	8.0	4
174	Trends in insulin resistance: insights into mechanisms and therapeutic strategy. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	132
175	Effect of Short-term Vitamin D Supplementation on the Alterations of Glycemic Variables in Response to Exhaustive Eccentric Exercise in Patients with Non-alcoholic Fatty Liver. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 229-234.	0.4	0
176	Editorial: Mitochondrial Biology and Its Role in Metabolic Diseases. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	0
177	The association between diabetes and obesity with Dengue infections. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	2.7	3
178	Cypenositides ameliorate high-fat diet-induced non-alcoholic steatohepatitis via farnesoid X receptor activation. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	4
179	Extrahepatic factors in hepatic immune regulation. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
180	Hepatocyte leukotriene B4 receptor 1 promotes NAFLD development in obesity. <i>Hepatology</i> , 2023, 78, 562-577.	7.3	14
181	Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification. <i>Atherosclerosis</i> , 2022, 357, 51-59.	0.8	13
182	Detangling the interrelations between MAFLD, insulin resistance, and key hormones. <i>Hormones</i> , 2022, 21, 573-589.	1.9	16
183	Rats with high aerobic capacity display enhanced transcriptional adaptability and upregulation of bile acid metabolism in response to an acute high-fat diet. <i>Physiological Reports</i> , 2022, 10, .	1.7	2
184	Pathogenesis from Inflammation to Cancer in NASH-Derived HCC. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 855-867.	3.7	5

#	ARTICLE	IF	CITATIONS
185	The adipocyte supersystem of insulin and cAMP signaling. <i>Trends in Cell Biology</i> , 2023, 33, 340-354.	7.9	15
186	Combined exposure to PM2.5 and high-fat diet facilitates the hepatic lipid metabolism disorders via ROS/miR-155/PPAR $\alpha$ pathway. <i>Free Radical Biology and Medicine</i> , 2022, 190, 16-27.	2.9	6
187	Integrating the contributions of mitochondrial oxidative metabolism to lipotoxicity and inflammation in NAFLD pathogenesis. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2022, 1867, 159209.	2.4	11
188	Association between Mediterranean Diet and Fatty Liver in Women with Overweight and Obesity. <i>Nutrients</i> , 2022, 14, 3771.	4.1	7
189	Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective. <i>Pharmacological Research</i> , 2022, 184, 106426.	7.1	6
190	Declining muscle NAD <sup>+</sup> in a hyperandrogenism PCOS mouse model: Possible role in metabolic dysregulation. <i>Molecular Metabolism</i> , 2022, 65, 101583.	6.5	4
191	Non-Alcoholic Fatty Liver Disease and Steatohepatitis. , 2023, , 610-621.		2
192	Excessive Gluconeogenesis Causes the Hepatic Insulin Resistance Paradox and Its Sequelae. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
193	Update on Non-Alcoholic Fatty Liver Disease-Associated Single Nucleotide Polymorphisms and Their Involvement in Liver Steatosis, Inflammation, and Fibrosis: A Narrative Review. <i>Iranian Biomedical Journal</i> , 2022, 26, 252-268.	0.7	2
194	Glucocorticoid therapy is a risk factor for cardiovascular diseases. <i>Medical Herald of the South of Russia</i> , 2022, 13, 93-106.	0.4	0
195	Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	25
196	Association between de novo lipogenesis susceptibility genes and coronary artery disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 2883-2889.	2.6	4
197	Mechanism of action of <i>Orthosiphon stamineus</i> against non-alcoholic fatty liver disease: Insights from systems pharmacology and molecular docking approaches. <i>Saudi Pharmaceutical Journal</i> , 2022, , .	2.7	5
198	Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis. <i>Nature Metabolism</i> , 2022, 4, 1185-1201.	11.9	16
199	Approaches to Measuring the Activity of Major Lipolytic and Lipogenic Enzymes In Vitro and Ex Vivo. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11093.	4.1	2
200	Lactation alters the relationship between liver lipid synthesis and hepatic fat stores in the postpartum period. <i>Journal of Lipid Research</i> , 2022, 63, 100288.	4.2	2
201	NAFLD and thyroid function: pathophysiological and therapeutic considerations. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 755-768.	7.1	14
202	Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. <i>Clinical Science</i> , 2022, 136, 1347-1366.	4.3	56

#	ARTICLE	IF	CITATIONS
203	Associations between low-carbohydrate and low-fat diets and hepatic steatosis. <i>Obesity</i> , 2022, 30, 2317-2328.	3.0	4
204	Visualization and quantification of de novo lipogenesis using a FASN-2A-GLuc mouse model. <i>Annals of Translational Medicine</i> , 2022, 10, 958-958.	1.7	0
205	Resveratrol Supplementation in Obese Pregnant Rats Improves Maternal Metabolism and Prevents Increased Placental Oxidative Stress. <i>Antioxidants</i> , 2022, 11, 1871.	5.1	7
206	Schisantherin A alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	3.9	4
207	Helminth infection and helminth-derived products: A novel therapeutic option for non-alcoholic fatty liver disease. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
208	Worksite-based intensive lifestyle therapy has profound cardiometabolic benefits in people with obesity and type 2 diabetes. <i>Cell Metabolism</i> , 2022, 34, 1431-1441.e5.	16.2	10
209	An integrative approach to assessing effects of a short-term Western diet on gene expression in rat liver. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	1
210	Understanding the extracellular vesicle surface for clinical molecular biology. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	12.2	22
211	Change in fatty acid composition of plasma triglyceride caused by a 2 week comprehensive risk management for diabetes: A prospective observational study of type 2 diabetes patients with supercritical fluid chromatography/mass spectrometry-based semi-target lipidomic analysis. <i>Journal of Diabetes Investigation</i> , 0, .	2.4	1
212	Chronotherapy with a glucokinase activator profoundly improves metabolism in obese Zucker rats. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	5
213	Diabetes, Aging, and Insulin's Reponic Features: Review. <i>Current Diabetes Reviews</i> , 2023, 19, .	1.3	1
214	Leptin increases hepatic triglyceride export via a vagal mechanism in humans. <i>Cell Metabolism</i> , 2022, 34, 1719-1731.e5.	16.2	17
215	Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines. <i>Frontiers in Neuroscience</i> , 0, 16, .	2.8	8
216	The presence of diabetic retinopathy closely associated with the progression of non-alcoholic fatty liver disease: A meta-analysis of observational studies. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	4
217	Insights into the roles and pathomechanisms of ceramide and sphingosine-1-phosphate in nonalcoholic fatty liver disease. <i>International Journal of Biological Sciences</i> , 2023, 19, 311-330.	6.4	12
218	Lambda-cyhalothrin induces lipid accumulation in mouse liver is associated with AMPK inactivation. <i>Food and Chemical Toxicology</i> , 2023, 172, 113563.	3.6	1
219	Predictive Risk Factors of Nonalcoholic Fatty Liver Disease in a Lean Chinese Population. <i>Journal of Personalized Medicine</i> , 2022, 12, 1958.	2.5	4
220	Protein Targeting to Glycogen (PTC): A Promising Player in Glucose and Lipid Metabolism. <i>Biomolecules</i> , 2022, 12, 1755.	4.0	3

#	ARTICLE	IF	CITATIONS
221	Mechanistic insights into the pleiotropic effects of butyrate as a potential therapeutic agent on NAFLD management: A systematic review. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	11
222	Glycohemoglobin: A new warning strategy for non-alcoholic fatty liver disease: Study from the NHANES 2017- 2020. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	0
223	Nutritional, pharmacological, and environmental programming of NAFLD in early life. <i>American Journal of Physiology - Renal Physiology</i> , 2023, 324, G99-G114.	3.4	10
224	Trimethylamine N-Oxide Levels in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Metabolites</i> , 2022, 12, 1243.	2.9	17
225	Excessive gluconeogenesis causes the hepatic insulin resistance paradox and its sequelae. <i>Heliyon</i> , 2022, 8, e12294.	3.2	9
226	Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S244-S260.	8.9	7
227	Waist Circumference Is an Essential Factor in Predicting Insulin Resistance and Early Detection of Metabolic Syndrome in Adults. <i>Nutrients</i> , 2023, 15, 257.	4.1	9
228	Impact of physical exercise on metabolic dysfunction-associated fatty liver disease (MAFLD). <i>Brazilian Journal of Development</i> , 2023, 9, 735-755.	0.1	0
229	The effect of acute and chronic exercise on hepatic lipid composition. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2023, 33, 550-568.	2.9	2
230	NOD1 activation in 3T3-L1 adipocytes confers lipid accumulation in HepG2 cells. <i>Life Sciences</i> , 2023, 316, 121400.	4.3	1
232	An Egg White-Derived Peptide Enhances Systemic Insulin Sensitivity and Modulates Markers of Non-Alcoholic Fatty Liver Disease in Obese, Insulin Resistant Mice. <i>Metabolites</i> , 2023, 13, 174.	2.9	3
233	Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. <i>Nutrients</i> , 2023, 15, 687.	4.1	12
234	The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	5
235	Association of serum NOD-like receptor protein 3 levels with impaired fat tolerance and hypertriglyceridemia. <i>Endocrine Journal</i> , 2023, , .	1.6	0
237	mTORC1 syndrome (TorS): unified paradigm for diabetes/metabolic syndrome. <i>Trends in Endocrinology and Metabolism</i> , 2023, 34, 135-145.	7.1	3
238	An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2023, 78, 1048-1062.	3.7	35
239	Fructose drives de novo lipogenesis affecting metabolic health. <i>Journal of Endocrinology</i> , 2023, 257, .	2.6	0
240	A bibliometric analysis and visualization of nonalcoholic fatty liver disease from 2012 to 2021. <i>Clinical and Experimental Medicine</i> , 2023, 23, 1961-1971.	3.6	2

#	ARTICLE	IF	CITATIONS
241	Concise review of lipidomics in nonalcoholic fatty liver disease. <i>Diabetes and Metabolism</i> , 2023, 49, 101432.	2.9	5
242	Metabolic Syndrome and Its Association with Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2023, 27, 187-210.	2.1	9
243	De novo lipogenesis fuels adipocyte autophagosome and lysosome membrane dynamics. <i>Nature Communications</i> , 2023, 14, .	12.8	15
244	Postprandial triglycerides and fibroblast growth factor 19 as potential screening tools for paediatric nonalcoholic fatty liver disease. <i>Pediatric Obesity</i> , 2023, 18, .	2.8	0
246	The role of hepatokines in NAFLD. <i>Cell Metabolism</i> , 2023, 35, 236-252.	16.2	55
247	Cardiovascular disease in metabolic-associated fatty liver disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2023, 30, 81-86.	2.3	0
248	Common pathogenetic pathways of Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. <i>Current Diabetes Reviews</i> , 2023, 19, .	1.3	0
250	Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023?. <i>Nutrients</i> , 2023, 15, 1323.	4.1	6
251	Nutritional regulation of hepatic de novo lipogenesis in humans. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2023, 26, 65-71.	2.5	6
252	From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications. <i>Biomedicines</i> , 2023, 11, 883.	3.2	14
253	Persistent fasting lipogenesis links impaired ketogenesis with citrate synthesis in humans with nonalcoholic fatty liver. <i>Journal of Clinical Investigation</i> , 2023, 133, .	8.2	4
254	Establishment of a nonalcoholic fatty liver disease model by high fat diet in adult zebrafish. <i>Animal Models and Experimental Medicine</i> , 0, , .	3.3	2
255	Hormonal regulation of metabolism—recent lessons learned from insulin and estrogen. <i>Clinical Science</i> , 2023, 137, 415-434.	4.3	2
256	Mouse strain-dependent variation in metabolic associated fatty liver disease (MAFLD): a comprehensive resource tool for pre-clinical studies. <i>Scientific Reports</i> , 2023, 13, .	3.3	2
257	MPEP Attenuates Intrahepatic Fat Accumulation in Obese Mice. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6076.	4.1	1
258	Differential effects of medium- and long-term high-fat diets on the expression of genes or proteins related to nonalcoholic fatty liver disease in mice. <i>Food Science and Technology</i> , 0, 43, .	1.7	0
259	Integrated omics analysis for characterization of the contribution of high fructose corn syrup to non-alcoholic fatty liver disease in obesity. <i>Metabolism: Clinical and Experimental</i> , 2023, 144, 155552.	3.4	5
260	Unravelling the role of obesity and lipids during tumor progression. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1

#	ARTICLE	IF	CITATIONS
261	Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes. <i>Metabolites</i> , 2023, 13, 517.	2.9	2
263	Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL). <i>Molecular Metabolism</i> , 2023, 73, 101728.	6.5	6
264	Heterogeneity in the effect of marked weight loss on metabolic function in women with obesity. <i>JCI Insight</i> , 2023, 8, .	5.0	2
265	Temporal Relationship Between Insulin Resistance and Lipid Accumulation After Bariatric Surgery: a Multicenter Cohort Study. <i>Obesity Surgery</i> , 2023, 33, 1720-1729.	2.1	2
266	Physiological and pathological roles of lipogenesis. <i>Nature Metabolism</i> , 2023, 5, 735-759.	11.9	21
267	Sex, Nutrition, and NAFLD: Relevance of Environmental Pollution. <i>Nutrients</i> , 2023, 15, 2335.	4.1	10
268	Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9677.	4.1	3
270	Lean nonalcoholic fatty liver disease and sarcopenia. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
271	Metabolic Disturbance of High-Saturated Fatty Acid Diet in Cognitive Preservation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 8042.	4.1	1
272	Liver acts as a metabolic gate for the traumatic brain injury pathology: Protective action of thyroid hormone. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166728.	3.8	0
273	Diet and Exercise Exert a Differential Effect on Glucose Metabolism Markers According to the Degree of NAFLD Severity. <i>Nutrients</i> , 2023, 15, 2252.	4.1	1
274	Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2023, 15, 2323.	4.1	3
275	High fat in blood and body and increased risk of clinically diagnosed non-alcoholic fatty liver disease in 105,981 individuals. <i>Atherosclerosis</i> , 2023, 376, 1-10.	0.8	1
276	Liver Fat â€œ Gone, but Not Forgotten?. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2023, 16, 321-322.	4.5	0
277	Lipid droplet biogenesis and functions in health and disease. <i>Nature Reviews Endocrinology</i> , 2023, 19, 443-459.	9.6	49
278	The regulatory role of PI3K in ageing-related diseases. <i>Ageing Research Reviews</i> , 2023, 88, 101963.	10.9	2
280	Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1/AMPK signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2023, 165, 115113.	5.6	6
281	Opportunities and Challenges for Inhibitors Targeting Citrate Transport and Metabolism in Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 9229-9250.	6.4	2



#	ARTICLE	IF	CITATIONS
282	Preventive and therapeutic effects of natural products and herbal extracts on <sc>nonalcoholic fatty liver disease</sc>/<sc>nonalcoholic steatohepatitis</sc>. <i>Phytotherapy Research</i> , 2023, 37, 3867-3897.	5.8	2
283	Liver insulinization as a driver of triglyceride dysmetabolism. <i>Nature Metabolism</i> , 2023, 5, 1101-1110.	11.9	1
284	Predictive value of the Framingham steatosis index for cardiovascular risk: a nationwide population-based cohort study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	1
285	Nonalcoholic Fatty Liver Disease Incidence and Remission and Their Predictors During 7 Years of Follow-up Among Finns. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	3.6	0
286	Editorial: Diabetes and non-alcoholic fatty liver disease: points of physiological and mechanistic intersection and current co-therapeutic approaches. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0
287	The role of platelets in non-alcoholic fatty liver disease: From pathophysiology to therapeutics. <i>Prostaglandins and Other Lipid Mediators</i> , 2023, 169, 106766.	1.9	5
288	Dietary Regulation of Hepatic Triacylglycerol Contentâ€”the Role of Eucaloric Carbohydrate Restriction with Fat or Protein Replacement. <i>Advances in Nutrition</i> , 2023, , .	6.4	0
289	Aetiology of Type 2 diabetes in people with a â€œnormalâ€™ body mass index: testing the personal fat threshold hypothesis. <i>Clinical Science</i> , 2023, 137, 1333-1346.	4.3	6
290	MnO <sub>2</sub> nanoparticles and MnSO <sub>4</sub> differentially affected hepatic lipid metabolism through miR-92a/acs13-dependent de novo lipogenesis in yellow catfish <i>Pelteobagrus fulvidraco</i> . <i>Environmental Pollution</i> , 2023, 336, 122416.	7.5	2
291	Raspberry ketone ameliorates nonalcoholic fatty liver disease in rats by activating the AMPK pathway. <i>European Journal of Pharmacology</i> , 2023, 957, 176001.	3.5	1
292	TorS â€•Reframing a rational for type 2 diabetes treatment. <i>Diabetes/Metabolism Research and Reviews</i> , 2024, 40, .	4.0	0
293	Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice. <i>Cell Reports Medicine</i> , 2023, 4, 101193.	6.5	2
294	Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice. <i>Nature Metabolism</i> , 2023, 5, 1706-1725.	11.9	2
295	A high fat, high sugar diet induces hepatic Peroxisome proliferator-activated receptor gamma coactivator 1-alpha promoter hypermethylation in male Wistar rats. <i>Biochemical and Biophysical Research Communications</i> , 2023, 680, 25-33.	2.1	0
296	<i>Corydalis saxicola</i> Bunting total alkaloids improve NAFLD by suppressing de novo lipogenesis through the AMPK-SREBP1 axis. <i>Journal of Ethnopharmacology</i> , 2024, 319, 117162.	4.1	0
297	Nucleoside diphosphate kinases 1 and 2 regulate a protective liver response to a high-fat diet. <i>Science Advances</i> , 2023, 9, .	10.3	3
298	Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis. <i>European Journal of Pharmacology</i> , 2023, 957, 175989.	3.5	1
299	Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?. , 2023, 251, 108549.		3

#	ARTICLE	IF	CITATIONS
300	Hepatic fatty acid and glucose handling in metabolic disease: Potential impact on cardiovascular disease risk. <i>Atherosclerosis</i> , 2023, , 117237.	0.8	0
301	Divergent pathways of liver fat accumulation, oxidation, and secretion in lipodystrophy versus obesity-associated <sc>NAFLD</sc>. <i>Liver International</i> , 2023, 43, 2692-2700.	3.9	0
302	Carbohydrate, Protein, and Fat Metabolism in Obesity. , 2023, , 1-17.		0
303	Effects Of Exercise Training And Chlorogenic Acid Supplementation On Hepatic Lipid Metabolism In Prediabetes Mice. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 771-783.	4.7	1
304	Weight-independent effects of <sc>Roux-en-Y</sc> gastric bypass surgery on remission of nonalcoholic fatty liver disease in mice. <i>Obesity</i> , 2023, 31, 2960-2971.	3.0	2
305	Micropatterned primary hepatocyte co-culture (HEPATOPAC) for fatty liver disease modeling and drug screening. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
306	The role of autophagy in the treatment of type II diabetes and its complications: a review. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	2
307	Isotope Labeling and Biochemical Assessment of Liver-Triacylglycerol in Patients with Different Levels of Histologically-Graded Liver Disease. <i>Journal of Nutrition</i> , 2023, 153, 3418-3429.	2.9	2
308	Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery. <i>Journal of Controlled Release</i> , 2023, 363, 415-434.	9.9	3
309	Mechanism for FXR to regulate bile acid and glycolipid metabolism to improve NAFLD. <i>World Chinese Journal of Digestology</i> , 2023, 31, 797-807.	0.1	0
310	MiR-143-3p/FNDC5 axis: a novel regulator of insulin sensitivity. <i>Endocrine</i> , 2024, 83, 368-377.	2.3	1
311	Effects of hepatic mitochondrial pyruvate carrier deficiency on de novo lipogenesis and gluconeogenesis in mice. <i>IScience</i> , 2023, 26, 108196.	4.1	0
312	The Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Body Composition in Type-2 Diabetes Mellitus: A Narrative Review. <i>Diabetes Therapy</i> , 2023, 14, 2015-2030.	2.5	0
313	FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1. <i>Hepatology</i> , 0, , .	7.3	1
314	The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review. <i>European Journal of Clinical Pharmacology</i> , 2024, 80, 127-150.	1.9	1
315	The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. <i>Current Medical Research and Opinion</i> , 2024, 40, 59-68.	1.9	0
316	Molecular Aspects of MAFLD-New Insights on Pathogenesis and Treatment. <i>Current Issues in Molecular Biology</i> , 2023, 45, 9132-9148.	2.4	1
317	The Role of Epigenetic Control of Mitochondrial (Dys)Function in MASLD Onset and Progression. <i>Nutrients</i> , 2023, 15, 4757.	4.1	2

#	ARTICLE	IF	CITATIONS
318	Liver metabolism and disease. , 2024, , 559-565.		0
320	The Impact and Burden of Dietary Sugars on the Liver. <i>Hepatology Communications</i> , 2023, 7, .	4.3	2
321	Pharmacologic inhibition of lipogenesis for the treatment of NAFLD. <i>Journal of Hepatology</i> , 2024, 80, 362-377.	3.7	1
322	In-depth analysis of de novo lipogenesis in non-alcoholic fatty liver disease: Mechanism and pharmacological interventions. <i>Liver Research</i> , 2023, 7, 285-295.	1.4	0
323	Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	1
324	Replacement of dietary carbohydrate with protein increases fat mass and reduces hepatic triglyceride synthesis and content in female obese Zucker rats. <i>Physiological Reports</i> , 2023, 11, .	1.7	0
325	A medium-chain fatty acid analogue prevents hepatosteatosis and decreases inflammatory lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis. <i>PLoS ONE</i> , 2023, 18, e0295244.	2.5	0
326	Hepatoprotective efficacy and interventional mechanism of panaxanediol saponins component in high-fat diet-induced NAFLD mice. <i>Food and Function</i> , 0, , .	4.6	0
327	The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans. <i>Cell Metabolism</i> , 2023, 35, 1887-1896.e5.	16.2	5
328	MiR-192-5p Ameliorates Hepatic Lipid Metabolism in Non-Alcoholic Fatty Liver Disease by Targeting Yy1. <i>Biomolecules</i> , 2024, 14, 34.	4.0	0
329	Bayesian Single-Arm Meta-Analysis of Nonalcoholic Fatty Liver Disease in China in Recent 10 Years. <i>Advances in Clinical Medicine</i> , 2023, 13, 19692-19702.	0.0	0
330	What Does Sarcopenia Have to Do with Nonalcoholic Fatty Liver Disease?. <i>Life</i> , 2024, 14, 37.	2.4	0
331	The pathophysiology of MASLD: an immunometabolic perspective. <i>Expert Review of Clinical Immunology</i> , 0, , 1-12.	3.0	0
333	Early-life exposure to gestational diabetes mellitus predisposes offspring to pediatric nonalcoholic fatty liver disease. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2023, , .	1.3	0
334	Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon. <i>Current Hepatology Reports</i> , 2024, 23, 204-219.	0.9	0
335	Hexokinase-linked glycolytic overload and unscheduled glycolysis in hyperglycemia-induced pathogenesis of insulin resistance, beta-cell glucotoxicity, and diabetic vascular complications. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0
336	Development and Validation of a Risk Prediction Model for NAFLD: A Study Based on a Physical Examination Population. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 17, 143-155.	2.4	0
337	Association between nonalcoholic fatty liver disease and increased glucose-to-albumin ratio in adults without diabetes. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	0

#	ARTICLE	IF	CITATIONS
338	Cut microbiota and metabolite interface-mediated hepatic inflammation. <i>Immunometabolism</i> , 2024, 6, e00037.	1.6	0
339	Carbohydrate, Protein, and Fat Metabolism in Obesity. , 2023, , 267-282.		0
340	Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth. <i>Metabolism: Clinical and Experimental</i> , 2024, 154, 155811.	3.4	0
341	PyMIDA: A Graphical User Interface for Mass Isotopomer Distribution Analysis. <i>Analytical Chemistry</i> , 2024, 96, 2303-2308.	6.5	0
342	The metabolic profiles and body composition of non-obese metabolic associated fatty liver disease. <i>Frontiers in Endocrinology</i> , 0, 15, .	3.5	0
343	Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction. <i>Molecules</i> , 2024, 29, 709.	3.8	0
344	Association of Hepatic Steatosis and Fibrosis Indices With Insulin Sensitivity and Inflammation in the POP-ABC Study. <i>Journal of the Endocrine Society</i> , 2024, 8, .	0.2	0
345	Surveillance of the liver in type 2 diabetes: important but unfeasible?. <i>Diabetologia</i> , 2024, 67, 961-973.	6.3	0
346	Real-Time NMR-Based Drug Discovery to Identify Inhibitors against Fatty Acid Synthesis in Living Cancer Cells. <i>Analytical Chemistry</i> , 0, , .	6.5	0
347	Interleukin-27 as a novel player in alleviating hepatic steatosis: Mechanistic insights from an in vitro analysis. <i>Biochemical and Biophysical Research Communications</i> , 2024, 703, 149671.	2.1	0
348	Hepatic glycogenesis antagonizes lipogenesis by blocking S1P via UDPG. <i>Science</i> , 2024, 383, .	12.6	0
349	Depression and NAFLD risk: A meta-analysis and Mendelian randomization study. <i>Journal of Affective Disorders</i> , 2024, 352, 379-385.	4.1	0
350	Glucagon-like Peptide-1 Receptor Agonistsâ€™ A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD). <i>Children</i> , 2024, 11, 275.	1.5	0
351	Hepatopancreatic metabolic disorders and their implications in the development of Alzheimer's disease and vascular dementia. <i>Ageing Research Reviews</i> , 2024, 96, 102250.	10.9	0
352	Association between TyG index trajectory and new-onset lean NAFLD: a longitudinal study. <i>Frontiers in Endocrinology</i> , 0, 15, .	3.5	0
353	Metabolic flux analysis in adipose tissue reprogramming. <i>Immunometabolism</i> , 2024, 6, e00039.	1.6	0
354	Dimethylallylglycine Suppresses SREBP1c and Lipogenic Gene Expressions in Hepatocytes Independently of HIF1A. <i>Current Issues in Molecular Biology</i> , 2024, 46, 2386-2397.	2.4	0
355	Are all sugars equal? Role of the food source in physiological responses to sugars with an emphasis on fruit and fruit juice. <i>European Journal of Nutrition</i> , 0, , .	3.9	0

#	ARTICLE	IF	CITATIONS
356	Hepatic insulin resistance and muscle insulin resistance are characterized by distinct postprandial plasma metabolite profiles: a cross-sectional study. <i>Cardiovascular Diabetology</i> , 2024, 23, .	6.8	0
357	<i>Physalis peruviana</i> intake against noncommunicable chronic diseases: a biomedical approach. , 2024, , 255-270.		0
358	Interleaved trinuclear MRS for single-session investigation of carbohydrate and lipid metabolism in human liver at 7T. <i>NMR in Biomedicine</i> , 0, , .	2.8	0
359	The changes in liver function biomarker concentrations in South Africans with prediabetes above 18 years of age: Protocol for a Systematic Review (Preprint). <i>JMIR Research Protocols</i> , 0, , .	1.0	0
360	Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY3-36, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats. <i>Nutrients</i> , 2024, 16, 904.	4.1	0
361	<i>Bacteroides</i> and NAFLD: pathophysiology and therapy. <i>Frontiers in Microbiology</i> , 0, 15, .	3.5	0
362	Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches. <i>European Journal of Medical Research</i> , 2024, 29, .	2.2	0